To cite: Rabe APJ. Loke WJ.

Kalyani RN, et al. Impact

of SARS-CoV-2 infection

lupus ervthematosus in

cohort study. BMJ Open

bmjopen-2022-071072

on patients with systemic

England prior to vaccination:

a retrospective observational

2023;13:e071072. doi:10.1136/

Prepublication history and

for this paper are available

online. To view these files,

bmjopen-2022-071072).

please visit the journal online (http://dx.doi.org/10.1136/

Received 15 December 2022

Check for updates

C Author(s) (or their

employer(s)) 2023. Re-use

permitted under CC BY-NC. No

commercial re-use. See rights

and permissions. Published by

For numbered affiliations see

Professor Adrian Paul J Rabe;

Accepted 12 October 2023

additional supplemental material

BMJ Open Impact of SARS-CoV-2 infection on patients with systemic lupus erythematosus in England prior to vaccination: a retrospective observational cohort study

Adrian Paul J Rabe ^(a), ^{1,2} Wei Jie Loke ^(b), ³ Rubana N Kalyani ^(b), ⁴ Raj Tummala ^(b), ⁴ Heide A Stirnadel-Farrant ^(b), ⁵ John Were, ⁶ Kevin L Winthrop 107

ABSTRACT

Objectives Determine the prevaccination healthcare impact of COVID-19 in patients with systemic lupus erythematosus (SLE) in England.

Design Retrospective cohort study of adult patients with SLE from 1 May to 31 October 2020.

Setting Clinical Practice Research Datalink (CPRD) Aurum and Hospital Episode Statistics (HES) databases from general practitioners across England combining primary care and other health-related data.

Participants Overall, 6145 adults with confirmed SLE diagnosis ≥1 year prior to 1 May 2020 were included. Most patients were women (91.0%), white (67.1%), and diagnosed with SLE at age <50 (70.8%). Patients were excluded if they had a COVID-19 diagnosis before 1 May 2020.

Primary and secondary outcome

measures Demographics and clinical characteristics were compared. COVID-19 severity was determined by patient care required and procedure/diagnosis codes, COVID-19 cumulative incidence, hospitalisation rates, lengths of stay and mortality rates were determined and stratified by SLE and COVID-19 severity.

Results Of 6145 patients, 3927 had mild, 1288 moderate and 930 severe SLE at baseline. The majority of patients with moderate to severe SLE were on oral corticosteroids and antimalarial treatments. Overall. 54/6145 (0.88%) patients with SLE acquired and were diagnosed with COVID-19, with 45 classified as mild, 6 moderate and 3 severe COVID-19. Cumulative incidence was higher in patients with severe SLE (1.4%) compared with patients classified as mild (0.8%) or moderate (0.8%). Ten COVID-19-specific hospital admissions occurred (n=6 moderate; n=4 severe). Regardless of COVID-19 status, hospital admission rates and length of stay increased with SLE severity. Of 54 patients with SLE diagnosed with COVID-19, 1 (1.9%) COVID-19-related death was recorded in a patient with both severe SLE and severe COVID-19. Conclusions SLE severity did not appear to impact COVID-19 outcomes in this study. The COVID-19 pandemic is evolving and follow-up studies are needed to understand the relationship between COVID-19 and SLE.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- \Rightarrow This study provided unique insight into the outcomes of COVID-19 for patients with systemic lupus erythematosus (SLE) before the availability of COVID-19 vaccines.
- \Rightarrow Due to the nature of a database study, there were limitations in the data captured in the system.
- \Rightarrow The number of diagnosed COVID-19 cases was low in patients with SLE.
- \Rightarrow The information about secondary care prescriptions in this population was limited.

INTRODUCTION

Protected by copyright, including for uses related to text and data mining Since December 2019, infection with SARS-CoV-2, the causative agent of COVID-19, has caused significant morbidity and mortality ,-⊳ worldwide, with over 6.6 million deaths as l trair of December 2022.^{1 2} Case fatality rate of SARS-CoV-2 infection was estimated from data published by the WHO, as of December 2022, to be 0.8% in the United Kingdom pu simila and 1.0% globally.¹ Case fatality rates can vary substantially according to viral strain and pathogenicity and across countries and patient subgroups,^{3–8} with personal health status, including age and underlying diseases, significantly impacting the risk and prognosis g of SARS-CoV-2 infection.⁷ COVID-19 symptoms and disease state can vary in severity from mild flu-like symptoms to severe lifethreatening disease,⁹ with critical COVID-19 disease, leading to acute respiratory distress syndrome, sepsis and septic shock, cardiac disease and thromboembolic events such as pulmonary disease and multiple organ failure.¹⁰ ¹¹ Overall, the wide spectrum of symptoms and multisystem nature of this

BMJ

BM.J.

end of article.

Correspondence to

a.rabe@imperial.ac.uk

disease continue to make COVID-19 a global threat, especially to high-risk groups.^{11 12}

Systemic lupus erythematosus (SLE) is a heterogenous, chronic, autoimmune disease that presents as a range of clinical manifestations across organ systems, with variable severity, disease course and prognosis.^{13 14} Both the innate and adaptive immune responses are dysregulated in patients with SLE,¹⁴¹⁵ leading to the production of pathogenic auto-antibodies that cause inflammation and tissue damage.¹⁶ SLE disease activity is commonly controlled with immunosuppressive therapies; therefore, patients may be more susceptible to infection.¹³ Both SLE disease activity and prolonged glucocorticoid use contribute towards progressive organ damage.^{17–19}

SLE and COVID-19 are both complex, multisystem diseases. During the early stages of the pandemic, the British Society for Rheumatology (BSR) classified SLE patients as at normal, moderate or high risk of severe illness from COVID-19 depending on their disease symptoms and treatment²⁰; however, it has been difficult to determine whether patients with SLE are more susceptible to SARS-CoV-2 infection or severe presentations of COVID-19. Additionally, there is limited evidence if SLE treatments confer a protective or detrimental effect on SARS-CoV-2 infection in patients with SLE.²¹ While standard therapies and organ damage may make patients with SLE more susceptible to severe COVID-19, it is unclear what the full extent of COVID-19 disease complications may be for patients with SLE.^{22 23}

Our study aimed to examine COVID-19 impact on adult patients with SLE in England from May 2020 to October 2020, prior to the start of the COVID-19 vaccination programme and the emergence of key SARS-CoV-2 variants of concern, such as the delta variant. Data from



Figure 1 Schematic of study design and criteria for patient selection. Patients were stratified by SLE severity within the 12-month baseline period (May 2019 to May 2020). All patients were required to have valid data to be considered for evaluation in the follow-up period and to be considered at-risk of COVID-19 within the study. CPRD, Clinical Practice Research Datalink; HES, Hospital Episode Statistics; ID, index date; SLE, systemic lupus erythematosus.

BMJ Open: first published as 10.1136/bmjopen-2022-071072 on 22 November 2023. Downloaded from http://bmjopen.bmj.com/ on June 10, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

5

area-level deprivation, age and sex in England.²⁶ The CPRD Aurum database encompasses 60 million patient lives, with approximately 18 million patients currently registered.²⁷ CPRD Aurum records were linked to the HES database, which records information on inpatient admissions, outpatient appointments and accident and emergency attendances in England.²⁶ Relevant hospital admissions, including admission of patients with SLE who had COVID-19 as the primary diagnosis, were identified. CPRD records were also linked to the ONS database, which records annual mortality data registered by age, sex and selected underlying cause of death.^{28 29} Consent for sharing patient data with CPRD Aurum was provided by clinical practices, with individual-level opt-out choice offered and implemented on request.²⁶ Further information regarding these data sets is shown in online supplemental table 1.

Population

A flowchart describing patient selection procedures is shown in online supplemental figure 1. Eligible patients were aged 18 years or older presenting at primary or secondary care with one or more diagnosis codes for SLE, determined by database codes in primary care, or an International Classification of Diseases (ICD-10) code in secondary care. The first recorded diagnosis (the index diagnosis) of SLE was required to be prior to 1 May 2019. SLE was confirmed by inclusion of at least one subsequent diagnosis of SLE following the index diagnosis. Patients were required to have valid data available beyond 1 May 2020.

Patients were excluded if they had drug-induced, cutaneous or discoid lupus, or if they did not have a 'definitive code' anywhere in their CPRD record or HES to confirm diagnosis. Patients were also excluded if a diagnosis of COVID-19 was recorded prior to the beginning of the study observation period on 1 May 2020.

Disease severity classifications

The main variables calculated for each patient were SLE severity, determined at the beginning of the observation period, and COVID-19 severity, where applicable.

SLE disease severity

SLE disease severity subgroups (severe, moderate or mild) were determined based on published classification criteria, ³⁰ previously used in a retrospective cohort analysis study in the UK.³¹ Specifically, patients were classified as having severe SLE if they had a prescription of cyclophosphamide or rituximab or oral glucocorticoids at a dosage of $\geq 60 \text{ mg/day}$ prednisone equivalent and had $\geq 1 \text{ ICD-10}$ code for diagnosis of severe renal, cardiovascular, hepatic, gastrointestinal, neurological, ocular or other comorbidities. Patients were classified as having moderate SLE if they were prescribed immunosuppressants (excluding cyclophosphamide) or oral glucocorticoids at a dosage of 7.5 mg/day to <60 mg/day prednisone equivalent, and if they had $\geq 1 \text{ ICD-10}$ code for diagnosis of moderate renal,

cardiovascular, hepatic, gastrointestinal, neurological, ocular or other comorbidities. Patients whose SLE was not considered moderate or severe were defined as mild. SLE severity was evaluated from 12 months prior to study entry (1 May 2019 to 1 May 2020), and the highest severity observed within this period was recorded.

COVID-19 diagnosis and severity

Diagnosis of COVID-19 was identified using CPRD database codes in primary care and the HES ICD-10 code in secondary care. Patients with a confirmed COVID-19 diagnosis were stratified based on COVID-19 severity. COVID-19 severity was determined using the following

COVID-19 severity was determined using the following definitions: COVID-19 was deemed severe if, in the same admission, as a new COVID-19 diagnosis or with COVID-19 in the primary diagnosis position, the patient required critical/intensive care in any episode during admission, and/or required mechanical ventilation (Office of Population Censuses and Surveys–4 procedure code), and/or experienced shock or sepsis (ICD-10 diagnosis codes) and/or experienced organ failure not previously coded (heart, lung, kidney, liver) (ICD-10 code). COVID-19 was deemed moderate if the patient was hospitalised with a new COVID-19 diagnosis but did not meet the severe criteria. COVID-19 was deemed mild if the patient had any new COVID-19 diagnoses outside of secondary care.

Study outcomes

Outcomes were evaluated in all identified patients with SLE overall, and in mild, moderate and severe SLE subgroups. The total number and cumulative incidence of COVID-19 infections per calendar month from 1 May 2020 to 31 October 2020 were calculated and stratified by COVID-19 severity. Patient demographics and clinical disease characteristics with respect to both SLE severity and COVID-19 severity were also compared.

≥ Among patients with SLE who developed COVID-19, the following clinical outcomes were evaluated for each SLE subgroup and COVID-19 severity group: age at COVID-19 ğ diagnosis, acute case fatality rate of COVID-19 (defined as a patient death within 28 days of an initial COVID-19 diagnosis and reported within the ONS death registry over the total number of COVID-19 cases in the target population), COVID-19-specific hospitalisation rate and length of stay, all-cause hospital admission rate per 1000 patients and lengths of stay (bed days) among COVID-19 severity groups, including those without a COVID-19 diagnosis, and number of patients with respiratory distress, organ failure, or pneumonia and of patients requiring oxygen **g** therapy or mechanical ventilation.

Statistical analysis

This was a descriptive study and, therefore, no comparative statistical analyses were planned or performed. Descriptive statistics for the study population were calculated, including total numbers of patients, clinical and demographic profiles and length of time patients with SLE were followed since diagnosis and inclusion within the study. Cumulative incidence of COVID-19 infections was determined monthly. Right censoring was used for patients who had no record of outcomes by the end of the 6-month study period. Left censoring was mitigated through record review for at least 10 years prior to the index date of 1 May 2020.

Patient and public involvement

Patients and/or the public were not involved in the design, conduct, reporting or dissemination of this research.

RESULTS

Demographics and disease characteristics of patients with SLE

Overall, 6145 patients were included for analysis, with 3927 defined as having mild SLE, 1288 with moderate SLE and 930 with severe SLE. Demographics and SLE disease characteristics at the index date, both overall and according to SLE disease severity, are shown in table 1. The majority of patients with moderate to severe SLE were on oral corticosteroids and antimalarial therapy, according to primary care prescription data. A total of 4350/6145 (70.8%) patients were diagnosed with SLE at age <50 years, with a mean 42.2 years of age (SD 14.2) at diagnosis. Mean age (SD) of diagnosis was similar across SLE disease severity subgroups, with 42.0 (13.9) years for mild, 41.7 (14.9) years for moderate and 43.5 (14.7) years for severe SLE. The majority of patients were female (91.0%), and most patients were White (67.1%), with smaller proportions of patients of Black (11.7%) or Asian (10.2%) race. Overall, 80.0% of patients had a low Charlson comorbidity score (<2). The most prevalent comorbidities were hypertension (19.1%), asthma (17.9%), history of pneumonia (14.7%) and diabetes (12.4%).

Incidence of COVID-19 in patients with SLE

From 1 May 2020 to 31 October 2020, 54 (0.88%) of the 6145 patients with SLE were diagnosed with COVID-19. Of these 54 cases, 45 (83.3%) were classified as mild COVID-19, 6 (11.1%) were moderate and 3 (5.6%) were severe. Overall cumulative incidence of COVID-19 over the 6-month observation period and according to SLE severity subgroup is shown in figure 2. Cumulative incidence of total COVID-19 cases rose more steeply in patients with severe SLE compared with patients classified with mild or moderate SLE (figure 2). This difference was driven predominantly by an increase in mild COVID-19 cases in patients with severe SLE.

Demographics and disease characteristics of patients with and without COVID-19 are shown in table 2. Compared with the 6091 patients with SLE without COVID-19, the 54 patients with COVID-19 were slightly older (mean age 45.2 vs 42.1 years), with similar body mass indices (mean 25.9 vs 26.3), and a similar proportion was women (92.6% vs 91.0%). A greater proportion of patients with versus without COVID-19 had a Charlson comorbidity score of ≥ 2 (33.3% vs 19.9%) and

Š

had comorbidities, including diabetes (24.1% vs 12.3%), hypertension (27.8% vs 19.0%), history of pneumonia (25.9% vs 14.6%), asthma (22.2% vs 17.9%), and history of myocardial infarction (11.1% vs 3.5%). Of the 54 patients diagnosed with COVID-19, 31 had mild, 10 had moderate and 13 had severe SLE (table 2).

There was a trend towards patients with severe SLE also having a severe COVID-19 diagnosis (patients with severe SLE made up 9/45 (20.0%) of mild, 2/6 (33.3%) of moderate and 2/3 (66.7%) of severe COVID-19 cases); Protected however, there were small numbers of patients who had severe COVID-19 (n=3) (online supplemental figure 2).

Clinical outcomes

copyright, A summary of clinical outcomes is found in table 3. The mean age (SD) at COVID-19 diagnosis was 55.8 (17.8) years overall for all patients with SLE, 53.7 (16.2) years in patients with mild SLE, 69.1 (18.9) years in patients with moderate SLE and 54.1 (15.2) years in patients with luding severe SLE.

Hospitalisations

ę Among the 54 patients with SLE and COVID-19, there uses rela were 10 recorded COVID-19-specific hospitalisations, as defined by diagnostic codes in the primary diagnostic position in the same admission as was documented in the HES database (table 3). Note that one patient can be hospitalised multiple times. Of these hospitalisations, six 5 were for moderate COVID-19 (six patients) and four were e for severe COVID-19 (three patients). Of the six patients hospitalised with moderate COVID-19, one had mild, three had moderate and two had severe SLE; the mean <u>o</u> (SD) length of stay for these patients was 10.2 (6.2) days. Of the three patients hospitalised with severe COVID-19, ∃ one patient with severe SLE was hospitalised once, one patient with severe SLE was hospitalised two times, and ≥ one patient with mild SLE was hospitalised once; the mean (SD) length of stay was 18.0 (18.0) days. In total, uning, there were 2152 all-cause hospital admissions among the SLE cohort during the observation period, 96 of which occurred in patients diagnosed with COVID-19.

The all-cause hospital admission rate per 1000 patients increased with severity of SLE regardless of COVID-19 status (from 158 for mild SLE to 1125 for severe SLE in patients without COVID-19, and from 194 for mild SLE to 6385 for severe SLE in patients with COVID-19) (table 3). The all-cause mean hospital length of stay also increased **o** with severity of SLE regardless of COVID-19 status (from & 3.0 days for mild SLE to 6.4 days for severe SLE in patients without COVID-19 and from 0.3 days for mild SLE to 16.0 days for severe SLE in patients with COVID-19) (table 3).

Deaths

There were 45/6091 (0.74%) deaths among patients with SLE without a COVID-19 diagnosis and 2/54 (3.7%) deaths among patients with SLE who were diagnosed with COVID-19 (table 3). Only one death was deemed related

Table 1 Demographics and disease characteristics at index of patients with SLE according to SLE severity							
		SLE severity subg	roup				
Characteristics	All patients with SLE, N=6145	Mild, n=3927	Moderate, n=1288	Severe, n=930			
Age at SLE diagnosis, years, mean (SD)	42.2 (14.2)	42.0 (13.9)	41.7 (14.9)	43.5 (14.7)			
Age group, n (%)							
18–29	1301 (21.2)	804 (20.5)	318 (24.7)	179 (19.2)			
30–39	1557 (25.3)	1024 (26.1)	314 (24.4)	219 (23.5)			
40–49	1492 (24.3)	984 (25.1)	283 (22.0)	225 (24.2)			
50–59	1006 (16.4)	642 (16.3)	197 (15.3)	167 (18.0)			
60+	789 (12.8)	473 (12.0)	176 (13.7)	140 (15.1)			
Female, n (%)	5593 (91.0)	3598 (91.6)	1150 (89.3)	845 (90.9)			
Race, n (%)							
White	4123 (67.1)	2647 (67.4)	856 (66.5)	620 (66.7)			
Black	717 (11.7)	389 (9.9)	178 (13.8)	150 (16.1)			
Asian	627 (10.2)	372 (9.5)	157 (12.2)	98 (10.5)			
Mixed	119 (1.9)	81 (2.1)	18 (1.4)	20 (2.2)			
Other	152 (2.5)	98 (2.5)	33 (2.6)	21 (2.3)			
Unknown	407 (6.6)	340 (8.7)	46 (3.6)	21 (2.3)			
BMI, kg/m ² , mean (SD)	26.3 (5.9)	26.0 (5.9)	26.4 (6.1)	27.0 (5.7)			
Total time in cohort, patient days	1 104 535	706175	230998	167362			
Follow-up time, patient months, mean (SD)	5.99 (0.59)	5.99 (0.58)	5.98 (0.62)	6.00 (0.60)			
Primary care prescriptions during the baseline period, n (%)*)						
Oral corticosteroids	1951 (31.7)	449 (11.4)	1055 (81.9)	447 (48.1)			
Other corticosteroids	711 (11.6)	399 (10.2)	168 (13.0)	144 (15.5)			
Azathioprine	478 (7.8)	201 (5.1)	190 (14.8)	87 (9.4)			
Ciclosporin	55 (0.9)	18 (0.5)	11 (0.9)	26 (2.8)			
Methotrexate	435 (7.1)	199 (5.1)	108 (8.4)	128 (13.8)			
Mycophenolate	449 (7.3)	172 (4.4)	183 (14.2)	94 (10.1)			
Hydroxychloroquine/antimalarials	3248 (52.9)	1881 (47.9)	836 (64.9)	531 (57.1)			
Charlson comorbidity score distribution, n (%)							
0	3009 (49.0)	2439 (62.1)	432 (33.5)	138 (14.8)			
1	1906 (31.0)	1045 (26.6)	485 (37.7)	376 (40.4)			
2	679 (11.0)	267 (6.8)	230 (17.9)	182 (19.6)			
3	296 (4.8)	120 (3.1)	84 (6.5)	92 (9.9)			
4+	255 (4.1)	56 (1.4)	57 (4.4)	142 (15.3)			
Comorbidities, n (%)							
Hypertension	1172 (19.1)	514 (13.1)	318 (24.7)	340 (36.6)			
Asthma	1101 (17.9)	608 (15.5)	294 (22.8)	199 (21.4)			
Pneumonia (history)	902 (14.7)	396 (10.1)	255 (19.8)	251 (27.0)			
Diabetes	764 (12.4)	390 (9.9)	201 (15.6)	173 (18.6)			
Pleurisy	357 (5.8)	178 (4.5)	104 (8.1)	75 (8.1)			
Obesity	356 (5.8)	191 (4.9)	84 (6.5)	81 (8.7)			
Stroke (history)	306 (5.0)	153 (3.9)	65 (5.0)	88 (9.5)			

Continued

Table 1 Continued

		SLE severity subgroup				
Characteristics	All patients with SLE, N=6145	Mild, n=3927	Moderate, n=1288	Severe, n=930		
Myocardial infarction (history)	219 (3.6)	95 (2.4)	65 (5.0)	59 (6.3)		
ESRD or dialysis	89 (1.4)	19 (0.5)	23 (1.8)	47 (5.1)		
Arterial/venous thrombosis	53 (0.9)	5 (0.1)	1 (0.1)	47 (5.1)		
Nephritis	49 (0.8)	0	21 (1.6)	28 (3.0)		
Hypercholesterolaemia	44 (0.7)	21 (0.5)	9 (0.7)	14 (1.5)		
Haemolytic anaemia	21 (0.3)	1 (0.03)	11 (0.9)	9 (1.0)		

*Secondary care prescribed medications are not reported.

BMI, body mass index; ESRD, end-stage renal disease; SLE, systemic lupus erythematosus.

to COVID-19 and occurred in a patient diagnosed with SLE more than 10 years prior to this study, who was classified as having severe SLE and had multiple additional comorbidities. During this period, the patient received prescriptions of prednisone, methotrexate and rituximab. Death occurred during an admission for COVID-19. The second death caused by acute myocardial infarction occurred in a patient classified with mild SLE and mild COVID-19. Overall, the acute COVID-19 case fatality rate was 19 per 1000 patients with SLE.

DISCUSSION

Protected by copyright, inc We retrospectively evaluated the incidence and outcomes of COVID-19 among a large SLE cohort in England prior to the advent of vaccination from 1 May 2020 to 31 October, 2020. We found few cases of COVID-19 in õu this cohort over this time period, and among those, a small number were severe. Interestingly, the cumulauses relate tive incidence of total COVID-19 cases appeared greater in patients with severe SLE as compared with mild or moderate SLE, although this was driven predominantly by mild COVID-19 cases.

The overall incidence of COVID-19 in patients with SLE during the 6-month observation period was low (0.9%).



Figure 2 Cumulative incidence of COVID-19 diagnoses over the 6-month evaluation period according to SLE severity. No comparative inferential statistical analyses were performed; cumulative incidence of COVID-19 diagnoses across SLE subgroups was evaluated with descriptive statistics only. SLE, systemic lupus erythematosus.

ö

text

t and data mining, Al training, and similar technologies

Table 2 Demographics and disease characteristics at index of patients with SLE with and without COVID-19 diagnosis						
Characteristics	Without COVID-19, n=6091	With COVID-19, n=54				
SLE severity, n (%)						
Mild	3896 (64.0)	31 (57.4)				
Moderate	1278 (21.0)	10 (18.5)				
Severe	917 (15.1)	13 (24.1)				
Age at SLE diagnosis, years, mean (SD)	42.1 (14.2)	45.2 (15.8)				
Age group, n (%)						
18–29	1295 (21.3)	6 (11.1)				
30–39	1540 (25.3)	17 (31.5)				
40–49	1478 (24.3)	14 (25.9)				
50–59	999 (16.4)	7 (13.0)				
60+	779 (12.8)	10 (18.5)				
Female, n (%)	5543 (91.0)	50 (92.6)				
Race, n (%)						
White	4085 (67.1)	38 (70.4)				
Black	710 (11.7)	7 (13.0)				
Asian	620 (10.2)	7 (13.0)				
Mixed	118 (1.9)	1 (1.9)				
Other	152 (2.5)	0				
Unknown	406 (6.7)	1 (1.9)				
BMI, kg/m ² , mean (SD)	26.3 (5.9)	25.9 (6.1)				
Total time in cohort, patient days	1 094 913	9622				
Follow-up time, patient months, mean (SD)	5.99 (0.59)	5.94 (0.84)				
Primary care prescriptions during the baseline period, n (%)**						
Oral corticosteroids	1930 (31.7)	21 (38.9)				
Other corticosteroids	707 (11.6)	4 (7.4)				
Azathioprine	474 (7.8)	4 (7.4)				
Ciclosporin	54 (0.9)	1 (1.9)				
Methotrexate	433 (7.1)	2 (3.7)				
Mycophenolate	448 (7.4)	1 (1.9)				
Hydroxychloroquine/antimalarials	3224 (52.9)	24 (44.4)				
Charlson comorbidity score distribution, n (%)		()				
0	2998 (49.1)	21 (38.9)				
1	1891 (31.0)	15 (27.8)				
2	672 (11.0)	7 (13.0)				
3	292 (4.8)	4 (7.4)				
4+	248 (4 1)	7 (13 0)				
Comorbidities n (%)	2.00()					
Hypertension	1157 (19 0)	15 (27 8)				
Asthma	1089 (17.9)	12 (22 2)				
Pneumonia (history)	888 (14.6)	14 (25 9)				
Diabetes	751 (12 3)	13 (24 1)				
Pleurisy	355 (5.8)	2 (3 7)				
Obesity	351 (5.8)	5 (9.3)				
Stroke (history)	303 (5.0)	3 (5.6)				
Myocardial infarction (history)	213 (3.5)	6 (11.1)				

Continued

\mathbf{n}
6
\mathbf{O}

Characteristics	Without COVID-19, n=6091	With COVID-19, n=54
ESRD or dialysis	87 (1.4)	2 (3.7)
Arterial/venous thrombosis	52 (0.9)	1 (1.9)
Nephritis	49 (0.8)	0
Hypercholesterolaemia	44 (0.7)	0
Haemolytic anaemia	21 (0.3)	0

*Secondary care prescribed medications are not reported.

BMI, body mass index; ESRD, end-stage renal disease; SLE, systemic lupus erythematosus.

In the general population, COVID-19 incidence from 1 May 2020 to 31 October 2020 in England was approximately 1.3%.^{32 33} Low incidence of COVID-19 among patients with SLE could have been due to low testing rates, leading to underestimates of infection rates during this timeframe in combination with public health precautions used to prevent the spread of SARS-CoV-2.^{34 35}

Our study identified some differences between the demographic and clinical characteristics of patients with SLE who were diagnosed with COVID-19 and those who were not, including older age and the prevalence of comorbidities (diabetes, hypertension, history of pneumonia, asthma and history of myocardial infarction). The demographic and clinical differences were in line with previously identified risk factors for severe COVID-19 disease outcomes in the non-SLE population.^{12 36} Although, to our knowledge, studies linking SLE disease activity and susceptibility for being infected with SARS-CoV-2 have not yet been published, previous studies have shown an association between SLE severity and developing severe COVID-19.²³ Furthermore, SLE disease activity has been previously identified as a risk factor for serious non-SARS-CoV-2 infections (eg, urinary tract infection, lower respiratory tract infection) and, conversely, attainment of low disease activity state was protective against serious infections.³⁷

The BSR considers patients with SLE as at high risk of developing severe COVID-19 disease if they have poorly controlled disease/recent flares, are receiving high dosages of glucocorticoids or are receiving certain immunosuppressive drugs.²⁰ Patients classified as having severe SLE in this study would have been categorised as high risk during the pandemic and, therefore, would have been advised by the NHS to 'shield' and be less exposed to COVID-19 infection.^{20 38} Our findings suggest that this shielding did not completely circumvent the potentially increased COVID-19 infection risk for some SLE patients. Notably, testing was not available for the general population in England until 2021.³⁹ It would be difficult to extrapolate on the prioritisation of SLE patients in terms of COVID-19 testing. However, for patients to receive care in hospitals, a test would have been required.⁴⁰ Thus, in line with the objective of this study to examine the healthcare impact of COVID-19 in patients with SLE, COVID-19 testing would have been an assumed step for hospitalised

patients based on NHS guidance at the time⁴⁰ and was captured in our dataset.

captured in our dataset. During the height of the COVID-19 pandemic, the NHS prioritised treatment of patients with COVID-19 in hospitals, which led to patients with SLE receiving more care at home through phone consultations.^{41 42} This shift in SLE management may have led to prioritised hospital admissions for patients with SLE following a COVID-19 diagnosis. In this study, being diagnosed with COVID-19 at any severity was associated with an increased rate of use subsequent all-cause hospitalisation at any time after COVID-19 diagnosis and prolonged length of stay in those admissions compared with not having COVID-19; however, only 10 of the 2152 hospital admissions were deemed COVID-19 related. The mortality rate of **a** text COVID-19 in patients with SLE was low, and there was only one COVID-specific death, which occurred in a patient with severe SLE.

Study limitations include that this is a database study and, therefore, analyses are limited by the type of data and extent to which said data are captured in the system. As such, we likely underestimated the incidence of positive COVID-19 cases in patients with SLE. There may ≥ have been a selection bias for patients who had valid data available beyond 1 May 2020, as individuals who acquired COVID-19 prior to this date and died were not included. Deaths, hospitalisations and diagnosis outside of England were also not captured in our data set. These limitations are partially alleviated by the inclusion of a large number of patients with SLE in this study who were previously deemed to be representative of the UK population (>6100 patients out of an eligible >7700 patients).^{43 44} Although the CPRD Aurum database covers 16.45% of practices in the UK,⁴⁵ SLE is usually diagnosed by a rheumatologist or other specialists rather than in primary care.⁴⁶ Furthermore, only 2.7% of all patients opted-out from sharing **g** their clinical data for research purposes by September 2020.⁴⁷ The use of HES to search for SLE diagnosis likely also provided a reliable picture of SLE incidence in hospitalised patients in England.

Additional limitations include that SLE severity classification criteria used in this study did not include detailed SLE severity classification and was instead based on patients' prescribed medication and recorded ICD-10 codes for various comorbidities, which are challenging

Table 3 Clinical ou	3 Clinical outcomes in patients with SLE with and without COVID-19 according to SLE severity							
COVID-19	Without COVID-19				With COVID-19			
SLE severity	Total SLE, n=6091	Mild SLE, n=3896	Moderate SLE, n=1278	Severe SLE, n=917	Total SLE, n=54	Mild SLE, n=31	Moderate SLE, n=10	Severe SLE, n=13
All-cause								
Hospital admissions, n	2056	615	409	1032	96	6	7	83
Admission rate per 1000 patients	338	158	320	1125	1778	194	700	6385
Length of stay, bed days, mean (SD)	4.6 (11.9)	3.0 (8.6)	5.3 (12.7)	6.4 (15.0)	12.8 (10.3)	0.3 (0.6)	17.3 (5.1)	16.0 (10.9)
Total number of deaths	45	14	19	12	2	1	0	1
COVID-19-specific								
Age at COVID-19 diagnosis, mean (SD)	-	-	-	-	55.8 (17.8)	53.7 (16.2)	69.1 (18.9)	54.1 (15.2)
COVID-19 severity, n (%)								
Mild	n/a	n/a	n/a	n/a	45 (83.3)	29 (93.5)	7 (70.0)	9 (69.2)
Moderate					6 (11.1)	1 (3.2)	3 (30.0)	2 (15.4)
Severe					3 (5.6)	1 (3.2)	0 (0)	2 (15.4)
Hospital admissions, n	-	-	-	-	10	2	3	5
Admission rate per 1000 patients	-	-	-	-	185	65	300	385
Length of stay, bed days, mean (SD)								
Overall	-	-	-	-	2.1 (6.4)	0.03 (0.2)	4.4 (7.4)	5.4 (10.7)
Moderate COVID-19*	-	-	-	-	10.2 (6.2)	-	-	-
Severe COVID-19†	-	-	-	-	18.0 (18.0)	-	-	-
Total number of deaths within 28 days of COVID-19 diagnosis	-	-	-	-	1	0	0	1
COVID- specific deaths (COVID-19 listed as primary cause of death)	1	0	1‡	0	1	0	0	1
Acute COVID-19 case fatality rate per 1000 patients	-	-	-	-	19	0	0	77
COVID-19 outcomes and directed therapies, n (%)								
Organ failure	-	-	-	-	8 (14.8)	1 (3.2)	2 (20.0)	5 (38.5)
								Continued

Table 3 Continued

COVID-19	Without COVID-19			With COVID-19				
SLE severity	Total SLE, n=6091	Mild SLE, n=3896	Moderate SLE, n=1278	Severe SLE, n=917	Total SLE, n=54	Mild SLE, n=31	Moderate SLE, n=10	Severe SLE, n=13
Pneumonia	-	-	-	-	7 (13.0)	1 (3.2)	3 (30.0)	3 (23.1)
Respiratory distress	-	-	-	-	1 (1.9)	0 (0)	1 (10.0)	0 (0)
Oxygen therapy	-	-	-	-	0 (0)	0 (0)	0 (0)	0 (0)
Mechanical ventilation	-	-	-	-	0 (0)	0 (0)	0 (0)	0 (0)

*Based on n=6 patients with SLE, diagnosed with moderate COVID-19.

+Based on n=1 patient with SLE, diagnosed with severe COVID-19.

‡Patient did not have a hospital admission with COVID-19, but in the ONS data COVID-19 was listed on the death certificate. The diagnosis for this patient in HES was J18 (pneumonia, organism unspecified).

HES, Hospital Episode Statistics; ONS, Office for National Statistics; SLE, systemic lupus erythematosus.

to capture completely in healthcare databases. There were significant limitations in capturing secondary care prescriptions in this data set, resulting in limited numbers of biologic, cyclophosphamide and glucocorticoid use and a possible underestimation of other SLE prescriptions. Patients were classified as having mild, moderate or severe SLE; however, a dichotomous classification comparing mild to moderate/severe disease may better capture clinically relevant disease activity in this heterogeneous condition.⁴⁸ Furthermore, SLE severity was classified based on the highest severity status within the 12-month timeframe prior to study entry, and disease activity/treatment could change during this period. However, the highest severity was considered in order to look at the 'worst case scenario' in assessing SLE patients for the objectives in the study. Sample size was also low due to the small number of diagnosed COVID-19 cases among these patients with SLE. Overall, the data used in this study represent a 'snapshot' of time in the fastmoving landscape of the COVID-19 pandemic. This provided unique insight into this SLE population prior to the availability of COVID-19 vaccines and was both a strength and a limitation of the study.

Treatment recommendations and preventive strategies for COVID-19 have been evolving quickly, making it challenging to evaluate the risk of SLE and its therapies alone in the absence of vaccination or native infection. The population included in this analysis was vaccinenaïve; however, since the study period (May 2020 to October 2020), a large-scale vaccination scheme has been introduced in the UK.⁴⁹ The start date was chosen due to the lack of widespread community testing in the UK prior to this date. Inclusion of COVID-19 diagnoses prior to this date would capture only the most severe hospitalised cases, underestimating the true incidence and overestimating severity of infections within this time period. Some patients with SLE were considered a high-risk group and were eligible to receive their first COVID-19 vaccination in the UK from February

Protected by copyright, includ 2021.⁵⁰ Findings of this study of vaccine-naïve patients with SLE may not be translatable to vaccinated patients with SLE as vaccines have changed the prognosis of COVID-19 in the UK⁵¹ but may be of interest in coun-COVID-19 in the UK³⁷ but may be of interest in coun-tries with lower vaccination rates and less controlled stages of the COVID-19 pandemic. Additionally, it is known that different SARS-CoV-2 variants have differing virulence characteristics,^{4 23 52} which could be impacted by SLE-related disease or treatment factors and further $\overline{\mathbf{5}}$ influenced by primary immunity acquired from native SARS-CoV-2 infection or prior vaccination.^{52 53} Therefore, studies such as the one presented here provide an important evaluation of COVID-19 in a prevaccination ő population of patients with SLE for future analysis to a build on. Vaccination against COVID-19 is reported to be safe and efficacious in patients with SLE with minimal risk of flares, and continued analysis of COVID-19 vaccination data will be useful in understanding the longterm impact of vaccination in patients with SLE.^{23 54 55}

CONCLUSIONS

In conclusion, analysis of this large retrospective cohort study of 6145 patients with SLE in England suggested that SARS-CoV-2 infection was more prevalent in patients with severe versus mild or moderate SLE; despite small group sizes, SLE severity did not appear to impact COVID-19 outcomes. Results from this study provide a unique snapshot into the outcomes of COVID-19 for patients with SLE in England during the prevaccine phase of the pandemic, when government-imposed safety measures were in place. Given the evolving nature of the COVID-19 pandemic, including changes in safety measures, vaccination rates, diagnostic methods and treatment options as well as the infectiousness and pathogenicity of new SARS-CoV-2 variants, follow-up studies are needed to fully understand the impact of COVID-19 on patients with SLE in other geographic regions over a longer period of time.

6

Author affiliations

¹BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK
²Primary Care and Public Health, Imperial College London, London, UK
³East and North Hertfordshire NHS Trust, Lister Hospital, Stevenage, UK
⁴BioPharmaceuticals R&D, AstraZeneca US, Gaithersburg, Maryland, USA
⁵Oncology Business Unit, Global Medical Affairs, AstraZeneca, Cambridge, UK
⁶Research Department, Health iQ Limited, London, UK

⁷Department of Infectious Diseases, Oregon Health & Science University, Portland, Oregon, USA

Acknowledgements Data analysis was performed by Health IQ LTD. Writing assistance was provided by Kelly M. Hunter, PhD, of JK Associates Inc., part of Fishawack Health. This work was supported by funding from AstraZeneca.

Contributors APJR, WJL, RNK, RT and HAS-F designed the research study. APJR, WL conducted the research. APJR, WJL, RNK, HAS-F and JW performed the analysis. APJR, WJL, RNK, RT, HAS-F, JW and KW contributed to the data interpretation and revised each draft for important intellectual content. All authors read and approved the final manuscript. APJR is acting as guarantor.

Competing interests APJR, RNK, RT and HAS-F are employees of and stockholders in AstraZeneca. HAS-F is a stockholder of GlaxoSmithKline (GSK). KW has served as a consultant to AbbVie, AstraZeneca, Bristol Myers Squibb (BMS), Eli Lilly & Company, Galapagos, Gilead, GSK, Novartis, Pfizer, Roche, Regeneron, Sanofi, and Union Chimique Belge (UCB); and has received grant/research support from BMS and Pfizer.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval This study used data that existed in an anonymised, structured format that contained no personal patient information. The study protocol was reviewed and approved by CPRD's Independent Scientific Advisory Committee (application number 21_000327) on 9 March 2021. Linkage of datasets was performed using anonymised and pseudonymised patient identification codes and was undertaken by NHS Digital, following study protocol approval. The CPRD obtains research ethics approval annually for receiving and supplying patient data for public health research from the UK's Health Research Authority Research Ethics Committee; no additional ethics approval is required for observational studies in public health research using CPRD Aurum data.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. Data underlying the findings described in this article may be obtained in accordance with AstraZeneca's data sharing policy described at https://astrazenecagrouptrials. pharmacm.com/ST/Submission/Disclosure

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/ licenses/by-nc/4.0/.

ORCID iDs

Adrian Paul J Rabe http://orcid.org/0000-0001-5237-0677 Wei Jie Loke http://orcid.org/0000-0003-2266-5938 Rubana N Kalyani http://orcid.org/0000-0003-1198-3391 Raj Tummala http://orcid.org/0000-0002-5506-4445 Heide A Stirnadel-Farrant http://orcid.org/0000-0003-0734-0422 Kevin L Winthrop http://orcid.org/0000-0002-3892-6947

REFERENCES

 World Health Organization. WHO Coronavirus (COVID-19) Dashboard 2022. Available: https://covid19.who.int/ [Accessed 9 Dec 2022].

Open access

- 2 Park SE. Epidemiology, virology, and clinical features of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19). *Clin Exp Pediatr* 2020;63:119–24.
- 3 Hasan MN, Haider N, Stigler FL, *et al.* The global case-fatality rate of COVID-19 has been declining since may 2020. *Am J Trop Med Hyg* 2021;104:2176–84.
- 4 Toyoshima Y, Nemoto K, Matsumoto S, *et al.* SARS-CoV-2 genomic variations associated with mortality rate of COVID-19. *J Hum Genet* 2020;65:1075–82.
- 5 Ballow M, Haga CL. Why do some people develop serious COVID-19 disease after infection, while others only exhibit mild symptoms? J Allergy Clin Immunol Pract 2021;9:1442–8.
- 6 Castro MC, Gurzenda S, Macário EM, et al. Characteristics, outcomes and risk factors for mortality of 522 167 patients hospitalised with COVID-19 in Brazil: a retrospective cohort study. BMJ Open 2021;11:e049089.
- 7 Tsang HF, Chan LWC, Cho WCS, *et al.* An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. *Expert Rev Anti Infect Ther* 2021;19:877–88.
- 8 Li Q, Wu J, Nie J, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell 2020;182:1284–94.
- 9 Centers for Disease Control and Prevention. Symptoms of COVID-19 2022. Available: https://www.cdc.gov/coronavirus/2019ncov/symptoms-testing/symptoms.html#print [Accessed 9 Dec 2022].
- 10 Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy 2020;75:1564–81.
- 11 Zaim S, Chong JH, Sankaranarayanan V, et al. COVID-19 and multiorgan response. Curr Probl Cardiol 2020;45:100618.
- 12 Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ 2020;368:m1198.
- 13 Fanouriakis A, Kostopoulou M, Alunno A, et al. Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019;78:736–45.
- 14 Katsuyama T, Tsokos GC, Moulton VR. Aberrant T cell signaling and subsets in systemic lupus erythematosus. *Front Immunol* 2018;9:1088.
- 15 Morawski PA, Bolland S. Expanding the B cell-centric view of systemic lupus erythematosus. *Trends Immunol* 2017;38:373–82.
- 16 Liu Z, Davidson A. Taming lupus-a new understanding of pathogenesis is leading to clinical advances. *Nat Med* 2012;18:871–82.
- 17 Sheane BJ, Gladman DD, Su J, et al. Disease outcomes in glucocorticosteroid-naive patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2017;69:252–6.
- 18 Al Sawah S, Zhang X, Zhu B, et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort. Lupus Sci Med 2015;2:e000066.
- 19 Bruce IN, O'Keeffe AG, Farewell V, *et al*. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. *Ann Rheum Dis* 2015;74:1706–13.
- 20 LUPUS UK. Lupus & Coronavirus (COVID-19). Available: https:// www.lupusuk.org.uk/coronavirus/#amiatrisk [Accessed 17 Mar 2023].
- 21 Ramirez GA, Gerosa M, Beretta L, *et al.* COVID-19 in systemic lupus erythematosus: data from a survey on 417 patients. *Semin Arthritis Rheum* 2020;50:1150–7.
- 22 Fernandez-Ruiz R, Paredes JL, Niewold TB. COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. *Transl Res* 2021;232:13–36.
- 23 Mehta P, Gasparyan AY, Zimba O, *et al*. Systemic lupus erythematosus in the light of the COVID-19 pandemic: infection, vaccination, and impact on disease management. *Clin Rheumatol* 2022;41:2893–910.
- 24 Department of Health & Social Care;. Coronavirus (COVID-19) Scaling up our testing programmes. 2020. Available: https://assets. publishing.service.gov.uk/government/uploads/system/uploads/ attachment_data/file/878121/coronavirus-covid-19-testing-strategy. pdf [Accessed 24 May 2020].
- 25 Majeed A, Pollock K, Hodes S, et al. Implementation of COVID-19 vaccination in the United Kingdom. *BMJ* 2022:e070344.
- 26 Wolf A, Dedman D, Campbell J, et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. Int J Epidemiol 2019;48:1740–1740g.
- 27 Medicines & Healthcare Products Regulatory Agency NIHR. Clinical Practice Research Datalink. 2022. Available: https://cprd.com/

Open access

- 28 Gallagher AM, Dedman D, Padmanabhan S, et al. The accuracy of date of death recording in the clinical practice research datalink GOLD database in England compared with the office for national statistics death registrations. *Pharmacoepidemiol Drug Saf* 2019;28:563–9.
- 29 Harshfield A, Abel GA, Barclay S, *et al*. Do GPs accurately record date of death? A UK observational analysis. *BMJ Support Palliat Care* 2020;10:e24.
- 30 Garris C, Jhingran P, Bass D, et al. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan. J Med Econ 2013;16:667–77.
- 31 Langham J, Barut V, Samnaliev M, *et al.* Disease severity, flares and treatment patterns in adults with systemic lupus erythematosus in the UK: a real-world observational retrospective cohort analysis. *Rheumatol Adv Pract* 2021;5:rkab061.
- 32 Office of National Statistics. England population mid-year estimate, population estimates. 2021. Available: https://www.ons.gov. uk/peoplepopulationandcommunity/populationandmigration/ populationestimates [Accessed 24 May 2022].
- 33 UK Health Security Agency. Coronavirus (COVID-19) in the UK. 2022. Available: https://coronavirus.data.gov.uk/details/cases?areaType= nation&areaName=England [Accessed 10 Apr 2022].
- 34 GOV.UK. Coronavirus (COVID-19): guidance. Available: https:// www.gov.uk/government/collections/coronavirus-covid-19-list-ofguidance#full-publication-update-history [Accessed 22 Mar 2023].
- 35 Martindale A-M, Pilbeam C, Mableson H, et al. Perspectives on COVID-19 testing policies and practices: a qualitative study with scientific advisors and NHS health care workers in England. *BMC Public Health* 2021;21:1216.
- 36 Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature* 2020;584:430–6.
- 37 Ko T, Koelmeyer R, Li N, et al. Predictors of infection requiring hospitalization in patients with systemic lupus erythematosus: a time-to-event analysis. Semin Arthritis Rheum 2022;57:152099.
- 38 NHS. Shielded patient list. Available: https://digital.nhs.uk/ coronavirus/shielded-patient-list#:~:text=Shielded%20Patient% 20List%20(SPL)%20web,Digital%20on%2030%20June%202022 [Accessed 17 Mar 2023].
- 39 GOV.UK. Twice weekly rapid testing to be available to everyone in England. 2021. Available: https://www.gov.uk/government/ news/twice-weekly-rapid-testing-to-be-available-to-everyonein-england#:~:text=Everyone%20in%20England%20will%20be, April%2C%20the%20government%20has%20announced.&text= universal%20testing%20offer-,Everyone%20in%20England% 20will%20be%20able%20to%20access%20free%2C%20 regular,April%2C%20the%20government%20has%20announced [Accessed 6 Apr 2023].
- 40 NHS. Healthcare associated COVID-19 infections further action. June 2020. Available: https://www.england.nhs.uk/coronavirus/wpcontent/uploads/sites/52/2020/06/Healthcare-associated-COVID-19infections--further-action-24-June-2020.pdf [Accessed 6 Apr 2020].
- 41 Murphy M, Scott LJ, Salisbury C, et al. Implementation of remote consulting in UK primary care following the COVID-19 pandemic: a mixed-methods longitudinal study. Br J Gen Pract 2021;71:e166–77.

- 42 Nune A, Iyengar KP, Ahmed A, et al. Impact of COVID-19 on rheumatology practice in the UK-a pan-regional rheumatology survey. *Clin Rheumatol* 2021;40:2499–504.
- 43 Rees F, Doherty M, Grainge M, et al. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. Ann Rheum Dis 2016;75:136–41.
- 44 Walley T, Mantgani A. The UK general practice research database. *Lancet* 1997;350:1097–9.
- 45 Medicines & Healthcare Products Regulatory Agency CPRD. CPRD Aurum. 2022. Available: https://cprd.com/cprd-aurum-may-2022dataset [Accessed 4 Apr 2023].
- 46 LUPUS UK. Diagnosis. Available: https://www.lupusuk.org.uk/ diagnosis/ [Accessed 4 Apr 2023].
- 47 NHS. National data opt-out. 2020. Available: https://digital.nhs.uk/ data-and-information/publications/statistical/national-data-opt-out/ september-2020 [Accessed 4 Apr 2023].
- 48 Speyer CB, Li D, Guan H, *et al.* Comparison of an administrative algorithm for SLE disease severity to clinical SLE disease activity index scores. *Rheumatol Int* 2020;40:257–61.
- 49 UK Health Security Agency. COVID-19: the green book, Chapter 14A. Coronavirus (COVID-19) vaccination information for public health professionals. 2022. Available: https://assets.publishing.service. gov.uk/government/uploads/system/uploads/attachment_data/file/ 1057798/Greenbook-chapter-14a-28Feb22.pdf
- 50 NHS. NHS offers COVID jab to clinically vulnerable and people 65 to 69. Available: https://www.england.nhs.uk/2021/02/nhsoffers-covid-jab-to-clinically-vulnerable-and-people-65-to-69/ [Accessed 24 May 2022].
- 51 Public Health England. Impact of COVID-19 vaccines on mortality in England: December 2020 to February 2021. In: *Public Health England Report*. 2021. Available: https://assets. publishing.service.gov.uk/government/uploads/system/uploads/ attachment_data/file/972592/COVID-19_vaccine_impact_on_ mortality_240321.pdf
- 52 Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 2021;19:409–24.
- 53 Choi JY, Smith DM. SARS-CoV-2 variants of concern. Yonsei Med J 2021;62:961–8.
- 54 Felten R, Kawka L, Dubois M, *et al.* Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study. *Lancet Rheumatol* 2021;3:e613–5.
- 55 Saxena A, Engel AJ, Banbury B, et al. Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City. *Lancet Rheumatol* 2022;4:e582–5.
- 56 Clinical Practice Research Datalink. CORYLUS UK: A retrospective observational cohort study of the impact of COVID-19 on systemic lupus erythematosus patients in England using data from linked primary and secondary care databases. 2021. Available: https://cprd. com/protocol/corylus-uk-retrospective-observational-cohort-studyimpact-covid-19-systemic-lupus [Accessed 9 Dec 2022].